Public Profile

Sangui Biotech International, Inc.

Sangui Biotech International, Inc., often referred to as Sangui Biotech, is a pioneering company headquartered in Delaware, USA. Founded in 2001, the firm operates primarily in the biotechnology sector, focusing on innovative solutions for medical and therapeutic applications. With a commitment to advancing healthcare, Sangui Biotech has developed a range of unique products, including cutting-edge blood substitutes and advanced wound care technologies. The company has achieved significant milestones, positioning itself as a leader in the field of biopharmaceuticals. Its core offerings are distinguished by their ability to enhance patient outcomes and improve quality of life. With a strong presence in both domestic and international markets, Sangui Biotech continues to drive innovation and maintain a competitive edge in the rapidly evolving biotechnology landscape.

DitchCarbon Score

How does Sangui Biotech International, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

15

Industry Average

Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

19

Industry Benchmark

Sangui Biotech International, Inc.'s score of 15 is lower than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.

9%

Sangui Biotech International, Inc.'s reported carbon emissions

Sangui Biotech International, Inc., headquartered in Delaware, currently does not have any publicly available carbon emissions data for the most recent year, nor do they have specified reduction targets or climate pledges. This absence of data suggests that the company may still be in the early stages of formalising its climate commitments or reporting on its carbon footprint. In the context of the biotechnology industry, many companies are increasingly focusing on sustainability and reducing their carbon emissions across all scopes—Scope 1, 2, and 3. While Sangui Biotech has not disclosed specific initiatives or targets, it is essential for companies in this sector to align with industry standards and best practices to mitigate climate impact. As the global emphasis on climate action intensifies, it will be crucial for Sangui Biotech to establish clear commitments and transparent reporting to enhance its sustainability profile and contribute to broader environmental goals.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Sangui Biotech International, Inc.'s primary industry is Health and social work services (85), which is low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. Sangui Biotech International, Inc. is headquartered in DE, which has a rank of medium, indicating medium grid carbon intensity.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Sangui Biotech International, Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers